Technical Analysis for VXL - Vaxil Bio Ltd.

Grade Last Price % Change Price Change
D 0.015 0.00% 0.000
VXL closed unchanged on Friday, April 19, 2024, on 7 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Wide Bands Range Expansion 0.00%
Fell Below 20 DMA Bearish 50.00%
Fell Below 50 DMA Bearish 50.00%
Narrow Range Bar Range Contraction 50.00%

   Recent Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vaxil Bio Ltd. Description

Vaxil Bio Ltd., formerly Emerge Resources Corp., is an immune-oncology biotechnology company. The Company is engaged in research and development of ImMucin vaccine to treat cancer. The Company develops immunotherapies, including neoantigen peptide products, and antibodies to treat cancer and infectious diseases. The Company offers VaxHit platform, which allows for identification, isolation and production of specific antigen-based immunotherapy products. The Company offers its products from VaxHit technology, which uses the signal peptide (SP) domain in selected targets as core antigens. The Company's product, ImMucin, which has received orphan drug status and designed for the treatment of multiple myeloma (MM) cancer. The Company's ImMucin is in Phase I clinical trial to treat antigen specific immunotherapies; SPmAb2 and SPmAb6 are in pre-clinical stage to treat SP specific antibodies, and MTbuVax is in pre-clinical stage to treat anti-infectives.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Health Medicine Identification Clinic Drug Biotechnology Disease Cancer Biology Therapy Diseases Clinical Trial Oncology Immunology Peptide Antibodies Antigen Immune System Immunotherapy Anti Infectives Antibody Immunotherapies Infectious Disease Infectious Diseases Multiple Myeloma Vaccine

Is VXL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.035
52 Week Low 0.01
Average Volume 159,257
200-Day Moving Average 0.016
50-Day Moving Average 0.013
20-Day Moving Average 0.012
10-Day Moving Average 0.012
Average True Range 0.003
RSI (14) 57.98
ADX 28.37
+DI 35.938
-DI 19.010
Chandelier Exit (Long, 3 ATRs) 0.012
Chandelier Exit (Short, 3 ATRs) 0.018
Upper Bollinger Bands 0.017
Lower Bollinger Band 0.007
Percent B (%b) 0.83
BandWidth 81.356
MACD Line 0.000
MACD Signal Line -0.001
MACD Histogram 0.0006
Fundamentals Value
Market Cap 1.68 Million
Num Shares 112 Million
EPS -0.01
Price-to-Earnings (P/E) Ratio -1.25
Price-to-Sales 0.00
Price-to-Book 53.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.015
Resistance 3 (R3) 0.015 0.015 0.015
Resistance 2 (R2) 0.015 0.015 0.015 0.015
Resistance 1 (R1) 0.015 0.015 0.015 0.015 0.015
Pivot Point 0.015 0.015 0.015 0.015 0.015
Support 1 (S1) 0.015 0.015 0.015 0.015 0.015
Support 2 (S2) 0.015 0.015 0.015 0.015
Support 3 (S3) 0.015 0.015 0.015
Support 4 (S4) 0.015